ClinicalTrials.gg
RecruitingNCT06382818PROBAUpdated Mar 12, 2026

Personalization of Breast Radiotherapy According to Loco-regional Recurrence Risk and Toxicity Probability

An interventional study of COHORT A and COHORT B in Breast Cancer, sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Institut du Cancer de Montpellier - Val d'Aurelle · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
854
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 44 studies in Breast Neoplasms by Institut du Cancer de Montpellier - Val d'Aurelle — 14 open to participants now, 17 under way, none of them phase 3. Breast Neoplasms · Institut du Cancer de Montpellier - Val d'Aurelle.

Planned enrollment
4th of 38
854 · median 148
Started
2025
with 3 others
No phase
29 of 44
12 open now
Primary completion
2028-03
later than 10 of 16 live
Registered
43rd of 44
by date

Among the 44 studies in Breast Neoplasms by Institut du Cancer de Montpellier - Val d'Aurelle, this one is the 4th largest by planned enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2025, is one of 29 with no phase, reaches primary completion later than 10 of the 16 other live ones, and was the 43rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

14 of the 44 studies in Breast Neoplasms by Institut du Cancer de Montpellier - Val d'Aurelle are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Breast Neoplasms by Institut du Cancer de Montpellier - Val d'Aurelle, or all of them as a file.
02

Study summary

Our objective is based on a personalized approach of adjuvant breast radiotherapy by selecting patients according to tumor recurrence and toxicity risk.

Read the detailed description

Breast cancer is the most common cancer in women in the world and remains a major public health burden with 25% of all cancer cases and 15% of all cancer deaths among females. The Incidence has increased with the introduction of mammography screening and continues to rise, mainly due to population aging; meanwhile, breast cancer survival has significantly improved over the past decades.

Adjuvant radiotherapy (RT) is an essential component of the treatment. After breast surgery for invasive carcinoma, RT is commonly used and delivered without considering the different tumor subtypes, unless the node involvement risk, because it decreases the rate of local recurrence and by this way, specific mortality. The " one size fits all " approach is widely applied, with two main options: breast or chest wall only radiotherapy or breast or chest wall plus nodes radiotherapy. Rare are the centers that discuss IMRT use, external partial breast irradiation, adaptive breast necessity, etc….

  1. Breast cancer and loco-regional recurrence risk Ten-year cancer specific survival exceeds 70%, with 89% survival for local and 62% for regional disease. The risk of recurrence is high during the first two years after the initial diagnosis for patients with hormonal receptor (HR)-negative breast cancer, but rapidly decreases below the recurrence risk of HR-positive tumors.

    Loco-regional recurrence (LRR) occurs in 5-15% of cases treated with breast conservative surgery (BCS) plus adjuvant radiotherapy (RT) or mastectomy and is considered an independent poor prognostic factor6. The management of LRR requires a multidisciplinary approach. Total mastectomy is the standard of care for isolated LRR after BCS. However, secondary BCS ± RT is an alternative approach that could be discussed case by case.

    Parameters to predict the risk of recurrence are those included in the NHS UK updated PREDICT score such as age, node status, tumor grade, proliferation index, Her2 and hormone receptor expression.

  2. Adjuvant breast radiotherapy and subcutaneous toxicity probability Severe but also moderate toxicities after curative-intent radiotherapy (RT), such as fibrosis, retraction or telangiectasia with poor cosmetic outcome can have a negative impact on quality of life following breast cancer and a marked effect on subsequent psychological outcome. Multiple factors are known to increase the risk of radiation toxicity including individual radiosensitivity9. While the toxicity risks for patients are well-established, determining an individual's normal tissue radiosensitivity is rarely possible before treatment.

    Nevertheless, current practice standards often prescribe radiation dose and volume without regard to individual radiosensitivity.

    In that context, a normal tissue radiosensitivity test that includes a rapid (72h) radiosensitivity assay based on flow cytometric assessment of radiation-induced CD8 (cytotoxic T cells 8) T-lymphocyte apoptosis (RILA) was developed by Ozsahin et al. A prospective study was conducted to determine whether the RILA assay could help identifying patients at high risk of severe toxicities. The RILA assay was performed in 399 patients with different cancer types before RT. Findings confirmed that patients who developed severe toxicities displayed a compromised apoptotic response.

    More recently, the RILA assay was validated in a prospective multicenter trial with more than 500 patients with breast cancer. The negative predictive value for grade ≥2 breast fibrosis was 91% for RILA scores ≥20% and the positive predictive value was 22% for RILA scores \<12% (the overall prevalence of grade ≥2 breast fibrosis was estimated at 14%). For the first time, RILA as a continuous variable was significantly associated with toxicities. Recently, the French results have been validated by a prospective European trial with similar predictive values of the RILA.

    In the CO-HO-RT trial, the RILA assay was used as the main stratification factor and no late toxicity occurred in patients with a RILA score >16%.

    In 2022, the RILA assay was included in the French recommendation (RECORAD) as the only validated predictive test for post-radiotherapy toxicity in a large, multi-center, prospective study.

    Based on these data, the NovaGray RILA Breast® test has been developed and combine both a biological analysis (radio-induced lymphocyte apoptosis) and an algorithmic analysis.

    The NovaGray RILA Breast is an vitro diagnostic medical device (IVMD) pertaining CE-mark. This prognostic test that assesses the risk of developing grade 2+ breast fibrosis at 36 months following radiotherapy. The test is performed on a blood draw and results are provided within a week, which does not delay the beginning of the radiotherapy.

  3. Matrix approach according to tumor recurrence and toxicity risk When using a predictive radiosensitivity test in clinical practice, an alternative treatment must be available to the patient in case of an unfavourable result, i.e. an adjustment in the radiotherapy protocol (change in fractionation or total dose), the addition or elimination of a concomitant treatment (e.g. chemotherapy) or the absolute contraindication to radiotherapy in highly radiosensitive patients for whom the treatment-related risk may be greater than the expected benefit.

Based on tumor control probability (TCP) and normal tissue complication probability (NTCP) we can group the patients into four situations described below.

  1. Clinical situation #1 : High TCP(Tissue Complication Probability) / Low NTCP (Normal Tissue Complication Probability) : COHORT A This circumstance is the optimum situation: a high local control probability and a low risk of developing toxicity. In this situation, the total dose of radiotherapy could be limited to the strict necessity since the probability of tumor control is already high. However, alternative fractionations such as moderate hypofractionated can be proposed to shorten the duration of treatment. In breast cancer, a regimen delivering 42.5 Gy in 16 fractions or 40 Gy in 15 fractions can be offered according to the Canadian or UK (united kingdom) regimen,. Recently, hypofractionated regimen are becoming more extreme with shorten fractionation regimen over 5 weeks or over 1 week . From a radiobiological and economic standpoint, these short regimens can provide a benefit in terms of quality of life with a lower cost of treatment.

    All of them are now included in the recommendations of the French National Society of Radiation Oncology and the French National Cancer Institute (INCa, Cancers du sein - Recommendations et outils d'aide à la pratique (e-cancer.fr)). All are considered as an option in daily clinical practice.

  2. Clinical situation #2 : High TCP / High NTCP : COHORT B In this situation, the patient is at risk of developing toxicity, but the probability of tumor control is high). In those cases, possible alternatives to radiotherapy may be discussed such as surgical treatment alone. In breast cancer, this can mean offering total mastectomy for a small tumor (possibly with immediate breast reconstruction) to postpone the indication of adjuvant radiotherapy. For a tumor with a very favorable prognosis, namely after 65 years old, avoiding radiotherapy after breast surgery may also be an option. In that case, treatment with partial irradiation of the breast (using external technique or brachytherapy) can also be proposed, to improve the long-term cosmetic results, while ensuring good local control.

    All of them are now included in the recommendations of the French National Society of Radiation Oncology. All are considered as an option in daily clinical practice.

  3. Clinical situation #3 : Low TCP / Low NTCP : COHORT C In that situation, the patient is at low risk of developing toxicity but the probability of tumor control is low. One of the possibilities is to increase the total dose of radiotherapy, namely with a localized boost within the tumor bed in invasive disease 5 and nodes irradiation according to the HypoG trial.

    This treatment is also included in the recommendations of the French National Society of Radiation Oncology.

  4. Clinical situation #4 : Low TCP / High NTCP : COHORT D This is the most unfavourable situation, with a radiation-resistant tumor and a patient with a high risk of developing toxicity. Dose de-escalation cannot be proposed to decrease toxicity in such cases, as the risk of tumor recurrence may be too high. Alternative fractionations, such as hyperfractionation (moderate or high depending on the organs at risk) could however be useful by decreasing the risk of toxicity while retaining a satisfactory level of tumor control. These regimens have not been validated and discussions should be carried out on a case-by-case basis. However, the impact on the decrease of toxicity, especially late-onset toxicity, has yet to be demonstrated. If adjusted radiotherapy regimens are not feasible and standard oncological treatment administered, the radioprotection of normal tissue should be discussed using adaptive techniques as it could decrease the risk of toxicity while maintaining good tumor control.

In this specific COHORT, inclusion in a new clinical trial evaluating adaptive treatment will be proposed to the patient. In case of patient refusal or technique unavailable, a standard treatment available in the center for this indication will be delivered.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Radiotherapy breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General criteria (for all cohorts):

  1. Women ≥ 18 years old.
  2. Invasive breast cancer treated by conservative or radical surgery.
  3. Conservative breast cancer surgery or radical mastectomy.
  4. Indication of breast irradiation.
  5. Extension evaluation of disease will be proven negative (M0).
  6. Negative pregnancy test (blood or urine at the choice of investigator), to be carried out within 7 days of registration, for women of childbearing age only.
  7. Effective for women of childbearing age
  8. Must be geographically accessible for follow-up.
  9. Written and dated .
  10. Affiliated to the French national social security system.

    Cohort A and B:

    - Low risk of recurrence (all of the criteria)

    • pT1-T2
    • SBR (Scarff Bloom et Richardson grade) grade ≤ 2 (low grade)
    • ER+ and / or PR+ (hormone-receptor positive)
    • cN0/pN-
    • HER 2 -
    • Ki67 ≤10%

    pN- with T3-4 and grade 3 and internal tumor will be considered at high risk of recurrence and will be proposed node irradiation (and will be switched to COHORT C or D).

    Cohort C and D:

    - High risk of recurrence (pN+ and at least one of all) adapted from the UK PREDICT

    • ER- and PR-
    • amplified
    • pT3-4
    • SBR grade ≥ 3
    • KI67 > 10%

    Cohort A and C:

    • Low risk of breast toxicities identified by the NovaGray RILA Breast® test

    Cohort B and D:

    - High risk of breast toxicities identified by the NovaGray RILA Breast® test

Exclusion criteria

Exclusion Criteria:

  • 1. Patients with distant .

2. Patients with breast DCIS (ductal carcinoma in situ) 3. Concomitant bilateral breast cancer 4. Previous breast radiotherapy 5. Patients with previous or concomitant other (not breast cancer) within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who have had a previous other malignancy must have been disease free for at least five years.

6. Patients with other non-malignant systemic diseases (cardiovascular, renal, hepatic, lung embolism, etc.) which would prevent prolonged follow-up.

7. Patients known to be positive (no specific tests are required to determine the eligibility).

8. Patients known as hypersensitive to radiation 9. Patients treated with systemic drugs during the present study (Observational cohorts are accepted if the collection of data does not interfere with the current trial) 10. Pregnant or breast-feeding women 11. Patient unable to comply with study obligations for geographic, social, or physical reasons, or who is unable to understand the purpose and procedures of the study 12. Person deprived of their liberty or under protective custody or guardianship

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
854 participants (estimated)

Study arms

  • Other
    COHORT A

    In this cohort, the patients with low risk of recurrence and a low risk of breast toxicity

    Radiation: COHORT A

  • Other
    COHORT B

    For this cohort, patients with low risk of recurrence and a high risk of breast toxicity, will receive breast radiotherapy according to the investigator's decision among: * External partial : 40 Gy in 15 fractions to the partial breast only (tumorectomy bed). * Exclusive Brachytherapy: 30.1 Gy in 7 fractions or 32.0 Gy in 8 fractions of high-dose-rate brachytherapy in 5 days or as 50 Gy of pulsed-dose-rate brachytherapy over 5 treatment days. * Whole Breast Normo fractionated with Fixed Field Intensity Modulated radiotherapy(IMRT) Technique: 50 Gy in 25 daily fractions over 5 weeks +/- Sequential (+ 16 Gy/8fr) or SIB (simultaneous integrated boost) (60 Gy/25 fr) treatment for boost if applicable.

    Radiation: COHORT B

  • Other
    COHORT C

    For this cohort, patients with high risk of recurrence and a low risk of breast toxicity, will receive whole breast and nodes Hypofractionated VMAT and a localized simultaneous boost according to the HypoG01 schema protocol: VMAT Technique, 42.3 Gy in 18 fractions on all target volume on 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fractions).

    Radiation: COHORT C

  • Other
    COHORT D

    For this cohort, patients with high risk of recurrence and a high risk of breast toxicity, will receive breast radiotherapy based on available clinical trials: \- Whole Breast and Nodes Hypofractionated VMAT with adaptive treatment (margin reduction): HypoG01 Schema with VMAT Technique, 42.3 Gy in 18 fractions on all target volume over 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fr) In case of patient refusal or technique unavailable, a standard treatment available in the center for this indication will be delivered.

    Radiation: COHORT D

Interventions

  • RadiationCOHORT A

    IMRT radiotherapy on whole breast according to the investigator's decision among: * Moderate whole breast hypofractionated RT according to the START B schema with Fixed Field IMRT Technique: 40.05 Gy in 15 daily fractions over 3 weeks and a Sequential boost (+ 16 Gy/8 fr) or (+13.5/5 fr) if applicable. * Extreme whole breast hypofractionated RT according to : * The FAST schema: Once-a-week ultra-HypoRT with Fixed Field IMRT Technique, 28.5 Gy in 5 fractions in 5 weeks * The FAST-Forward schema: Very accelerated course of HypoRT with Fixed Field IMRT Technique, 26 Gy in 5 fractions in 5 consecutive days

  • RadiationCOHORT B

    Breast radiotherapy according to the investigator's decision among: * External partial VMAT: 40 Gy in 15 fractions to the partial breast only (tumorectomy bed). * Exclusive Brachytherapy: 30.1 Gy in 7 fractions or 32.0 Gy in 8 fractions of high-dose-rate brachytherapy in 5 days or as 50 Gy of pulsed-dose-rate brachytherapy over 5 treatment days. * Whole Breast Normo fractionated IMRT with Fixed Field IMRT Technique: 50 Gy in 25 daily fractions over 5 weeks +/- Sequential (+ 16 Gy/8fr) or SIB (60 Gy/25 fr) treatment for boost if applicable.

  • RadiationCOHORT C

    Whole breast and nodes Hypofractionated VMAT and a localized simultaneous boost according to the HypoG01 schema protocol: VMAT Technique, 42.3 Gy in 18 fractions on all target volume on 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fractions).

  • RadiationCOHORT D

    Breast radiotherapy based on available clinical trials: \- Whole Breast and Nodes Hypofractionated VMAT with adaptive treatment (margin reduction): HypoG01 Schema with VMAT Technique, 42.3 Gy in 18 fractions on all target volume over 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fr) In case of patient refusal or technique unavailable, a standard treatment available in the center for this indication will be delivered.

06

What researchers measure

Primary outcomes

  1. Rate of patients without any grade 2 or more fibrosis, nor radio-induced sarcoma

    Toxicity free survival is defined as the interval between date of inclusion and the occurrence of fibrosis grade 2 or more or radio-induced sarcoma. Patients without event at the analysis will be censored at the date of last follow-up.

    Time frame: at 10 years

Secondary outcomes

  1. Acute toxicity

    according to NCI-CTCAE v5 is defined as side effects observed

    Time frame: from the start of RT to 12 weeks post RT

  2. Late toxicity

    according to NCI-CTCAE v5 is defined as side effects observed

    Time frame: from 12 weeks post RT to 3, 5 and 10 years post RT

  3. Local recurrence rate (LRR)

    LRR will be deducted from the local recurrence survival defined as the interval between date of inclusion and the occurrence of local relapse. Patients without local relapse at the analysis will be censored at the date of last follow-up

    Time frame: at 3, 5, 10 years

  4. Relapse-free survival (RFS) rate

    RFS is defined as the interval between date of inclusion and the occurrence of relapse. Patients without relapse at the analysis will be censored at the date of last follow-up

    Time frame: at 3, 5, 10 years

  5. Overall survival (OS) rate

    OS is defined as the interval between date of inclusion and the occurrence of death, due to any cause. Patients alive at the analysis will be censored at the date of last follow-up.

    Time frame: at 3, 5, 10 years:

  6. Radiation-induced Breast Sarcoma prevalence

    Prevalence of Radio-induced Breast Sarcoma at 10 years will be estimated using the Kaplan-Meier method, and then described using rate at 10 years with its associated 95% confidence interval.

    Time frame: at 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2028, 36 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 36 months is close to that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2024
First posted
Apr 24, 2024
StartActual
Mar 6, 2025
Primary completionEst.
Mar 6, 2028
CompletionEst.
Mar 6, 2038
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06382818
Responsible party
Sponsor
First posted
Apr 24, 2024
Start date
Mar 6, 2025
Primary completion
Mar 6, 2028 (estimated)
Completion
Mar 6, 2038 (estimated)
Last update
Mar 12, 2026

Study contacts

MOUSSION AURORE
Contact
aurore.moussion@icm.unicancer.fr
0467613102
AZRIA DAVID
principal investigator · Institut du Cancer de Montpellier - Val d'Aurelle

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion